Publication | Open Access

57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

ImmunologyImmune Checkpoint InhibitorEgfr Mutant NsclcTki-naïve PatientsImmunotherapyMedicineRadiation OncologyNovel Therapy